| Patient | Benjamin Franklin |
|---|---|
| Date of birth | 1950-01-17 |
| Identifiers | MRN HR-EN004-SYN; SSN (made up) 000-04-3318 |
| Document date | 2026-09-14 |
| Author | Lydia Penhallow, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Gout, stone prevention, kidney, and blood pressure review at about six months. [S]
Mr. Franklin returns about six months after starting urate-lowering therapy. He had one gout flare, in the left knee ten weeks ago, treated with five days of prednisone; the knee culture grew nothing, and he has had no flare since. The potassium and urate checks planned for two to five weeks after his last visit were not drawn until that sick visit, at seven weeks. He takes allopurinol 300 mg, colchicine 0.6 mg, losartan, atorvastatin, and potassium citrate. His home jug shows about 2.3 L of urine a day. His home blood pressure averages 128/76. He voids well, with nocturia once. He walks 30 minutes most days and has lost 3 kg. [S]
| Element | Detail |
|---|---|
| Interval history | One left knee flare ten weeks ago, crystal-proven and culture-negative; none since |
| Missed checks | Potassium and urate planned for 2 to 5 weeks were drawn at the sick visit at seven weeks |
| Urine output | About 2.3 L a day by measuring jug |
| Home blood pressure | Average 128/76 mmHg |
| Medication tolerance | No rash, diarrhea, muscle aches, or stomach upset from potassium citrate |
| Weight | Down 3 kg since March |
| System | Result | Finding |
|---|---|---|
| Musculoskeletal | Negative | No joint pain or swelling since the knee flare; no muscle aches |
| Genitourinary | Negative | Good stream, nocturia once, no blood in the urine |
| Gastrointestinal | Negative | No nausea or abdominal pain on potassium citrate |
| Neurological | Negative | No dizziness on standing |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Hydrochlorothiazide 25 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2019-05-06 to 2026-03-02 | stopped | S |
| Losartan 50 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-03-02 | active | S |
| Allopurinol 100 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-03-02 to 2026-03-30 | completed | S |
| Allopurinol 100 mg oral tablet, two tablets (200 mg) by mouth daily | Two tablets by mouth daily | Oral route | 2026-03-30 to 2026-05-18 | completed | S |
| Allopurinol 300 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-05-18 | active | S |
| Colchicine 0.6 mg oral tablet, one tablet by mouth daily for flare prophylaxis | One tablet by mouth daily | Oral route | 2026-03-02 to 2026-09-14 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain, no more than 3 g a day | Two tablets every 6 hours as needed; maximum 6 tablets a day | Oral route | 2026-03-02 | active | S |
| Tamsulosin 0.4 mg oral capsule, one capsule by mouth at bedtime until surgery | One capsule by mouth at bedtime | Oral route | 2026-03-30 to 2026-04-20 | completed | S |
| Atorvastatin 20 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-03-30 | active | S |
| Potassium citrate 10 mEq extended-release tablet, one tablet by mouth twice daily with meals | One tablet by mouth twice daily with meals | Oral route | 2026-05-18 | active | S |
| Prednisone 20 mg oral tablet, two tablets (40 mg) by mouth each morning for 5 days | Two tablets by mouth each morning for 5 days, with food | Oral route | 2026-07-06 to 2026-07-10 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-09-14 | Body height | 175 | cm | S |
| 2026-09-14 | Body weight | 93.2 | kg | S |
| 2026-09-14 | Body mass index (BMI) [Ratio] | 30.4 | kg/m2 | S |
| 2026-09-14 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-09-14 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-09-14 | Heart rate | 68 | /min | S |
| 2026-09-14 | Respiratory rate | 14 | /min | S |
| 2026-09-14 | Body temperature | 36.6 | Cel | S |
| 2026-09-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-09-14 | Urate [Mass/volume] in Serum or Plasma | 5.4 | mg/dL | 3.5-7.2 mg/dL | Normal | S |
| 2026-09-14 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-09-14 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-09-14 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 26 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-09-14 | Urea nitrogen [Mass/volume] in Serum or Plasma | 21 | mg/dL | 8-23 mg/dL | Normal | S |
| 2026-09-14 | Creatinine [Mass/volume] in Serum or Plasma | 1.32 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-09-14 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 56 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 2026-09-14 | Glucose [Mass/volume] in Serum or Plasma | 97 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-09-14 | pH of Urine | 6.3 | [pH] | 4.5-8 [pH] | Normal | S |
| 2026-09-14 | US Urinary bladder Volume post void | 30 | mL | <=100 mL | Normal | S |
| 2026-09-14 | International Prostate Symptom Score [IPSS] | 5 | {score} | S |
Vital signs recorded on 2026-09-14; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well |
| Joints | No synovitis or tophi; left knee without effusion |
| Cardiovascular | Regular rhythm; no edema; pedal pulses palpable |
| Abdomen | No suprapubic tenderness |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Gout with recurrent flares, mostly in the right big toe, without tophi; synthetic modern diagnosis linked to his documented gout | active | confirmed | M1A.0710 | S — Synthetic modern diagnosis; his recurrent gout is documented in his own letters (D). |
| Bladder stone (2.6 cm, uric acid on analysis) with bladder outlet obstruction, removed by cystolitholapaxy; synthetic modern diagnosis linked to his documented stone | resolved | confirmed | N21.0 | S — Synthetic modern diagnosis confirmed by CT and cystoscopy; his stone is documented in his own letters (D), though its composition is not known. |
| Chronic kidney disease stage G3a A1 | active | confirmed | N18.31 | S — Synthetic diagnosis; no measure of kidney function from his lifetime exists. |
| Essential hypertension | active | confirmed | I10 | S — Synthetic diagnosis; no blood pressure from his lifetime exists. |
| Benign prostatic hyperplasia with lower urinary tract symptoms and bladder outlet obstruction, treated by transurethral resection | active | confirmed | N40.1 | S — Synthetic diagnosis made at the urology consultation as the probable cause of the bladder stone; the cause of his historical stone is not documented. |
| Acute gout flare of the left knee, crystal-proven, during urate-lowering titration; resolved | resolved | confirmed | M10.062 | S — Synthetic flare at an unscheduled visit; flares are common in the first months of urate-lowering therapy. It does not echo a dated historical attack. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Serum urate | Every 2 to 5 weeks while titrating; every 6 months once at target | Completed today | 5.4 mg/dL on allopurinol 300 mg: at target |
| Laboratory | Serum urate 2 to 5 weeks after raising allopurinol to 300 mg | Once after each dose change | Deferred | Not drawn in the window, a deviation from the protocol; the first value came at the July flare visit at seven weeks (5.9 mg/dL, unreliable during a flare). No change in management resulted, and today's 5.4 confirms the target. Corrective action: the standing order now prints at each visit |
| Laboratory | Potassium 2 to 4 weeks after starting potassium citrate with losartan in chronic kidney disease | Once after starting; then periodically | Deferred | Not drawn in the window, a deviation from the protocol; first checked at the July sick visit at seven weeks (4.7 mmol/L). No harm: potassium 4.6 today. Corrective action: potassium is added to the standing order whenever a potassium-raising drug is started |
| Laboratory | Metabolic panel | Every 6 months on an ARB; with each eGFR draw | Completed today | Potassium 4.6 mmol/L, bicarbonate 26 mmol/L, creatinine 1.32 mg/dL, eGFR 56 |
| Laboratory | Urine pH on alkalinization | With each follow-up on potassium citrate | Completed today | 6.3, within the goal |
| Medication safety | Flare prophylaxis | 3 to 6 months, longer if flares continue | Completed today | Stopped today after more than six months; urate at target and no flare for ten weeks |
| Examination | Office and home blood pressure | Every visit | Completed today | 128/76 mmHg office and home |
| Examination | Peripheral pulses | Every 2 to 3 years at 65 or older | Completed today | Pedal pulses palpable; no claudication |
| Survey | IPSS | Every follow-up; 1, 3, 6, and 12 months after a procedure | Completed today | 5 |
| Examination | Post-void residual | Post-procedural follow-up | Completed today | 30 mL |
| Survey | Three-month post-procedural urologic check | About 3 months after the procedure | Deferred | No separate visit was held at three months, a deviation from the follow-up schedule; urinary symptoms were reviewed and negative at the July sick visit. No harm: IPSS and residual are normal today |
| Laboratory | eGFR, urine albumin-creatinine ratio, hemoglobin, and KFRE | Yearly at G3a A1 | Up to date | Done in March (KFRE 0.2 percent at 2 years and 0.6 percent at 5 years, well below referral thresholds); due again next March |
| Laboratory | Calcium, phosphate, PTH, and vitamin D | Baseline at G3a, then every 6 to 12 months | Due | Normal in March; due next March |
| Laboratory | Lipid panel | Once at CKD diagnosis (KDIGO); yearly in the CMID hypertension schedule | Not indicated | On atorvastatin for kidney disease; KDIGO advises no routine repeat lipid testing |
| Medication safety | Medication review for NSAIDs and drug interactions | Every visit | Completed today | No NSAIDs; colchicine with atorvastatin caused no muscle symptoms, and colchicine stops today |
| Medication safety | Vaccination status | Yearly | Due | Influenza and RSV vaccines planned at next month's wellness visit |
| Self-management | Fluids, diet, alcohol, weight, and activity | Every visit | Completed today | About 2.3 L of urine a day; one glass of wine on most evenings; 3 kg weight loss; walking 30 minutes most days |
Goal progress:
Guideline basis: 2020 American College of Rheumatology Guideline for the Management of Gout (2020); Medical Management of Kidney Stones: AUA Guideline (2014, amended 2019); EAU Guidelines on Urolithiasis (including bladder stones) (2025); Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2023 amendment); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2017); CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, and benign prostatic hyperplasia monographs (2026)
Follow-up: Annual wellness visit next month. Serum urate, urine pH, and yearly kidney tests in six months. Next scheduled visit 2026-10-19: subsequent annual wellness visit. [S]